Status
Conditions
Treatments
About
The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.
Full description
MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke.
Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases.
The investigators hypothesis is that MPO concentrations and subsequent HDL dysfunction could be higher in ischemic strokes than in haemorrhagic ones. MPO could be a examined as a potent marker of early stage of ischemic stroke.
Plasma MPO levels could also be discriminant regarding the mimick strokes in patient exhibiting stroke clinical picture.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with less than 12 hours stroke clinical signs:
Exclusion criteria
112 participants in 3 patient groups
Loading...
Central trial contact
David COURET, MD; Christine JUHEL, PHD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal